Adherence to Dolutegravir and Outcome (DOLUTECAPS)

Caen University Hospital

Status: Unknown

Conditions: HIV

Study type: Observational

Funder types: Other

Identifiers

NCT02878642

13-184

Details and patient eligibility

About

The main assumption is that the dolutegravir can get virologic suppression to suboptimal adherence levels (between 80 and 95%, and after treatment interruptions) where other molecules are not capable, due to their pharmacokinetic/pharmacodynamic (pardonnance).

While the investigators goal is not to compare molecules (study with one arm) in terms of forgiveness, the results of this cohort in terms of forgiveness could be compared to other cohorts available.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV-1
• Age over 18 years
• Information letter signed
• ART (antiretroviral therapy) with at least 3 active molecules
• Patients starting treatment with dolutegravir (naïve to antiretroviral treatment, switch, virologic failure)

Exclusion criteria

• pregnant woman
• HIV-2
• Patient does not have responsibility for the observance of treatment (disorder of judgment, guardianship, institutionalization)
• Patient receiving aid incompatible with compliance with the use of electronic pillbox